Statin intolerance

Current Opinion in Lipidology
Ulrich LaufsWinfried März

Abstract

Adherence to hydroxymethylglutaryl-CoA reductase reductase inhibitor (statin) therapy correlates with cardiovascular mortality. Muscle symptoms are the most significant side-effects of statin therapy. This review article summarizes the current concepts of the diagnosis and clinical work-up of patients with statin-associated muscle symptoms (SAMS). SAMS represent a major barrier to maintain long-term persistence to statin treatment. SAMS reduce the quality of life and rare complications may extend to rhabdomyolysis. The molecular pathology of SAMS is heterogeneous. After exclusion of other causes of muscle symptoms the main principle of treatment is re-exposure to very low dose of statin and slow uptitration until the maximally tolerated dose is established. Using this approach the vast majority of patients can be treated with statins long term. For patients with SAMS that are not at low-density lipoproteins (LDL) goal with their maximally tolerated dose of statin combination therapy with ezetimibe and proprotein convertase subtilisin/kexin-9 inhibitors are available. Time and care is needed to address SAMS because they impair drug adherence. For most patients it is possible to continue the statin therapy. However, combination t...Continue Reading

References

Jan 1, 1971·Annals of Internal Medicine·W B KannelP M McNamara
May 7, 2002·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M PfeiferH W Minne
Jul 23, 2002·JAMA : the Journal of the American Medical Association·Cynthia A JackeviciusJack V Tu
Oct 2, 2002·Annals of Internal Medicine·Paul S PhillipsUNKNOWN Scripps Mercy Clinical Research Center
Jun 1, 2004·Nature Medicine·Eric P Hoffman, Gustavo A Nader
Apr 12, 2005·Annual Review of Pharmacology and Toxicology·James K Liao, Ulrich Laufs
May 20, 2005·Der Nervenarzt·K GertzM Endres
Oct 15, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Maria L UrsoPaul D Thompson
Nov 16, 2005·Archives of Neurology·Costanza LampertiSalvatore DiMauro
Dec 21, 2005·Biochemical and Biophysical Research Communications·Hiroyasu NabaTakuo Ogihara
Feb 3, 2006·Cardiovascular Drugs and Therapy·Eric BruckertBernard Bégaud
Apr 4, 2006·The American Journal of Cardiology·Malcolm Law, Alicja R Rudnicka
May 4, 2006·Muscle & Nerve·Georgirene D VladutiuPaul S Phillips
Nov 17, 2006·Pharmacogenetics and Genomics·Marja K PasanenMikko Niemi
Dec 21, 2006·Clinical Pharmacology and Therapeutics·Pertti J NeuvonenJanne T Backman
Mar 23, 2007·Lipids in Health and Disease·Jisun OhRobert A Hegele
May 12, 2007·The American Journal of Cardiology·Giuseppe CasoWilliam E Lawson
Jun 15, 2007·Lancet·Jane Armitage
Nov 8, 2007·The Journal of Pharmacology and Experimental Therapeutics·Cort S MadsenPhilip D Stein
Mar 6, 2008·JAMA : the Journal of the American Medical Association·Rebecca L WaberDan Ariely
Apr 3, 2008·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Steven K BakerMark A Tarnopolsky
May 2, 2008·Journal of General Internal Medicine·Catherine BuettnerKenneth J Mukamal
Jul 25, 2008·The New England Journal of Medicine·UNKNOWN SEARCH Collaborative GroupR Collins
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Nov 13, 2008·The Journal of Physiology·Joanne E MallinsonPaul L Greenhaff
Feb 11, 2009·Archives of Internal Medicine·Varda ShalevAnthony D Heymann
Feb 17, 2009·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·J SidawayR C Scott
Jul 8, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Markus G MohauptAnnette Draeger
Nov 6, 2009·Clinical Pharmacology and Therapeutics·M Niemi
Nov 27, 2009·Circulation Research·Michael J KnauerRommel G Tirona
Jan 1, 2010·Atherosclerosis·Abhijit GhatakPaul D Thompson
Apr 7, 2010·Expert Opinion on Drug Metabolism & Toxicology·Alice C Rodrigues
Aug 24, 2010·European Heart Journal·Ulrich LaufsMichael Böhm
Nov 19, 2010·The New England Journal of Medicine·Christopher P CannonUNKNOWN Determining the Efficacy and Tolerability Investigators
Feb 24, 2011·Expert Opinion on Drug Safety·Thura T Abd, Terry A Jacobson
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Jul 7, 2011·Current Medical Research and Opinion·Charles J GlueckNaila Goldenberg
Jul 29, 2011·Molecular Genetics and Metabolism·Georgirene D VladutiuRobert L Wortmann
Aug 2, 2011·The Journal of Toxicological Sciences·Hisakuni ObayashiAtsushi Sanbuissho
Aug 27, 2011·Atherosclerosis·Gualberto RuañoPaul D Thompson

❮ Previous
Next ❯

Citations

Jan 1, 2016·Lipids in Health and Disease·Maciej BanachAdrian Covic
Jul 20, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Winfried MärzUlrich Laufs
Sep 21, 2016·Expert Opinion on Drug Safety·Engi Abdel-Hady AlgharablyReinhold Kreutz
Jan 18, 2019·Circulation Research·Natalie C WardRobert H Eckel
Sep 24, 2019·The Annals of Pharmacotherapy·Devon JacobsJoshua Sullivan
Sep 20, 2019·Biomolecules·Maurizio Balestrino, Enrico Adriano
Oct 8, 2019·Journal of Atherosclerosis and Thrombosis·Kouji KajinamiUNKNOWN Statin Intolerance Clinical Guide Working Group; The Japan Society of Hepatology, Japanese Society of Neurology, Japan Ather
Jul 24, 2020·European Heart Journal·Ulrich Laufs, Berend Isermann
Aug 16, 2016·Molecular and Cellular Biochemistry·Qixiao JiangChunbo Wang
Apr 26, 2017·Basic Research in Cardiology·Simon GlerupKlaus-Dieter Schlüter
May 31, 2018·European Heart Journal. Cardiovascular Pharmacotherapy·Stefano AlbaniGianfranco Sinagra
Jan 24, 2019·Clinical Science·Natalie C WardGerald F Watts
Apr 3, 2020·Pharmacology Research & Perspectives·Felix H ZakirovAlexander N Orekhov
Nov 10, 2020·Archives of Endocrinology and Metabolism·Roberta de Pádua BorgesMarcello Casaccia Bertoluci

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
glycosylation
biopsy

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Deutsches Ärzteblatt International
Ulrich LaufsWinfried März
Current Opinion in Endocrinology, Diabetes, and Obesity
Ewa Dembowski, Michael H Davidson
Physical Medicine and Rehabilitation Clinics of North America
Sung C Ahn
Current Atherosclerosis Reports
Saadi A Siddiqi, Paul D Thompson
© 2022 Meta ULC. All rights reserved